Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: A multicenter romanian trial

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 4, 2011, Pages 377-382

  Gheorghe, Liana ^a   Iacob, Speranta ^a   Simionov, Iulia ^a   Vadan, Roxana ^a   Constantinescu, Ileana ^a   Caruntu, Florin ^b   Sporea, Ioan ^c   Grigorescu, Mircea ^d  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b The National Institute of Infectious Diseases 'Matei Bals'   (Romania)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Antiviral therapy; Hepatitis D; Peginterferon 2b

Indexed keywords

PEGINTERFERON ALPHA2B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD DISEASE; BODY WEIGHT; BREAST DISEASE; CHILL; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DELTA AGENT HEPATITIS; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EAR DISEASE; EYE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJECTION SITE REACTION; INNER EAR DISEASE; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; RESPIRATORY TRACT DISEASE; ROMANIA; SIDE EFFECT; SKIN DISEASE; THORAX DISEASE; TREATMENT RESPONSE; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BODY WEIGHT; CHI-SQUARE DISTRIBUTION; DRUG DOSAGE CALCULATIONS; FEMALE; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RNA, VIRAL; ROMANIA; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84055222290     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rizzetto M. Hepatitis D: the comeback? Liver Int 2009; 29(Suppl 1): 140-142.
2. Grigorescu M, Pascu O, Acalovschi M, Radu C. What is the real prevalence of the D virus infection in chronic hepatitis and liver cirrhosis in Romania? Rom J Gastroenterol 2003;12:179-182.
3. Gheorghe L, Popescu I, Iacob R, Iacob S, Gheorghe C. Predictors of death on the waiting list for liver transplantation characterized by a long waiting time. Transpl Int 2005;18:572-576.
4. Iacob S, Gheorghe L, Gheorghe C, et al. Predictive factors for the development of hepatocellular carcinoma in cirrhotic patients. Hepato-Gastroenterology 2004; 51 (Suppl I): 9.
5. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-1638.
6. Gheorghe L, Iacob S, Simionov I, et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 2005;14:329-335.
7. Farci P. Treatment of delta hepatitis with interferons. EASL monothemathic conference Istanbul, Turkey 2010; 40 (abstract).
8. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon a2b. Liver Int 2006: 26: 805-810.
9. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon α-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006;44:713-720.
10. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44:728-735.
11. Wedemeyer H, Yurdaydin C, Dalekos G, et al. 72 week data of the HIDIT-1 trial: a multicenter randomised study comparing peginterferon alpha-2a plus adefovir vs. peginterferon alpha-2a plus placebo vs. adefovir in chronic D hepatitis. J Hepatol 2007; 46: 4.
12. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
13. Rizzetto M, Verme G, Recchia S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of delta antigen: an active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983;98:437-441.
14. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatology 2010; 53: 834-840.
15. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:88-94.
16. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
17. Ferenci P, Formann E, Romeo R. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a. Am J Gastroenterol 2005; 100: 1626-1627.
18. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-331.
19. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferontherapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004;126:1740-1749.
20. Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferonalpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3: 123-128.
21. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217.